

CONGRATULATIONS!

Gail D’Onofrio, MD, MS, Albert E. Kent Professor of Emergency Medicine, Professor of Medicine and Public Health, Yale University was elected to the National Academy of Medicine



Sharon Levy, MD, MPH, Boston Children’s Hospital, Chief, Division of Addiction Medicine, was promoted to Professor of Pediatrics at Harvard Medical School



Roger Weiss, MD, Professor of Psychiatry at Harvard Medical School, and Chief of the Division of Alcohol, Drugs, and Addiction at McLean Hospital received the Founders Award from the American Academy of Addiction Psychiatry

Angela Haeny, PhD, Yale University, Assistant Professor of Psychiatry was recipient of the 2023 Early Career Investigator Award from the Translational Mechanisms of Behavior Change (MOBC) Satellite Meeting at the Research Society on Alcohol (RSA).



R. Kathryn McHugh, Ph.D. is the recipient of the 2023 Anne M. Cataldo Awardee for Excellence in Mentoring at McLean Hospital and received the award on October 17th, 2023

CTN-0131

Our Lead Node hosted the **Methadone Clinician Education and Support Training**, held on 10/2, in Fitkin Auditorium on the campus of Yale School of Medicine. Physicians, Nurse Practitioners, Physician’s Assistants, and pharmacists represented all 6 participating sites.

*Presenters included: **David Fiellin, MD, Study Lead Investigator;** **Zoe Weinstein, MD, MS, Study Co-Investigator;** Jef Bratberg, PharmD; Ayana Jordan, MD, PhD, Study Co-Investigator; David Frank, PhD; Brandy Robinson; **Jeanette Tetrault, MD, Study Co-Investigator;** and Richard Schottenfeld, MD, Study Co-Investigator

The CTN-0131 National Training took place via webinar 10/12-10/13.



UPCOMING!

AMERSA’s 47th Annual National Conference 11/2-4, 2023 in Washington, D.C.

New England Consortium Node Meeting , 11/9 8:00 am

Lead Node in Active Studies

CTN-031: Methadone or Enhanced Buprenorphine to Address Retention Among Patients Not Optimally Benefitting from Office-based Buprenorphine - a Hybrid Effectiveness/Implementation Trial

CTN-0126: Longitudinal Follow-Up of Individuals with Opioid Use Disorder

CTN-0100: Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (NIH HEAL Initiative)

CTN-0099: Emergency Department INitiated bupreNorphine and VALidatiON Network Trial (ED-INNOVATION) (NIH HEAL Initiative)

Participating in Active Studies

CTN-0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): A Pragmatic Randomized Trial Comparing Two Buprenorphine Formulations (NIH HEAL Initiative)

CTN-0098A/B: Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE) (NIH HEAL Initiative)

CTN-0112: Optimal Policies to Improve Methadone Maintenance Adherence Longterm (OPTIMMAL)

CTN-0116: Pharmacist-Integrated Model of Medication Treatment for Opioid Use Disorder

CTN-0122: Comprehensive Meta-Analysis of CTN Treatment Outcomes by Race and Sex

CTN-0125: Integrative Data Analysis of CTN Studies to Examine the Impact of Psychosocial Treatments for Black People who use Cocaine

CTN-0144: Better Together: Integrating MOUD in African American Community Settings

Studies in Development

CTN-0145: High vs Standard Buprenorphine ED Initiation

CTN-0146: A cohort study of pain, psychological, and drug use outcomes of adolescents after major surgery

PUBLICATIONS

Ren Boyu, Lipsitz Stuart R, **Weiss Roger D, Fitzmaurice Garrett M.** [Methods for handling missing binary data in substance use disorder trials.](#) Drug Alcohol Depend. 2023 Sep 1;250:110897. doi: 10.1016/j.drugalcdep.2023.110897. Epub 2023 Jul 13. PMID: 37544038.

Paschen-Wolff M, **Greenfield SF, Kathryn McHugh R,** Burlew K, Pavlicova M, Choo TH, Barbosa-Leiker C, Ruglass LM, Mennenga S, Rotrosen J, Nunes EV, Campbell ANC. [Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone \(BUP-NX\) or extended-release naltrexone \(XR-NTX\) for opioid use disorder.](#) Am J Addict. 2023 Aug 15. doi: 10.1111/ajad.13463. Epub ahead of print. PMID: 37583120.

New Publication including a NEC Node Participating Site (Boston Medical Center): Liu J, Pan Y, Nelson MC, Gooden LK, Metsch LR, Rodriguez AE, Tross S, Del Rio C, Mandler RN, Feaster DJ. [Strategies of Managing Repeated Measures: Using Synthetic Random Forest to Predict HIV Viral Suppression Status Among Hospitalized Persons with HIV.](#) AIDS Behav. 2023 Sep;27(9):2915-2931. doi: 10.1007/s10461-023-04015-1. Epub 2023 Feb 5. PMID: 36739589; PMCID: PMC10403627.

Cowan E, Perrone J, **Bernstein SL, Coupet E Jr, Fiellin DA, Hawk K,** Herring A, Huntley K, McCormack R, **Venkatesh A, D'Onofrio G.** [National Institute on Drug Abuse Clinical Trials Network Meeting Report: Advancing Emergency Department Initiation of Buprenorphine for Opioid Use Disorder.](#) Ann Emerg Med. 2023 Sep;82(3):326-335. doi: 10.1016/j.annemergmed.2023.03.025. Epub 2023 May 12. PMID: 37178101

McCormack RP, Rotrosen J, Gauthier P, **D'Onofrio G, Fiellin DA,** Marsch LA, Novo P, Liu D, **Edelman EJ,** Farkas S, Matthews AG, Mulatya C, Salazar D, Wolff J, Knight R, Goodman W, Williams J, **Hawk K** [Implementing Programs to Initiate Buprenorphine for Opioid Use Disorder Treatment in High-Need, Low-Resource Emergency Departments: A Nonrandomized Controlled Trial.](#) Ann Emerg Med. 2023 Sep;82(3):272-287. doi: 10.1016/j.annemergmed.2023.02.013. Epub 2023 May 2. PMID: 37140493

Karnik NS, Marsden J, McCluskey C, Boley RA, Bradley KA, Campbell CI, Curtis ME, **Fiellin D,** Ghitza U, Hefner K, Hser YI, **McHugh RK,** McPherson SM, Mooney LJ, Moran LM, Murphy SM, Schwartz RP, Shmueli-Blumberg D, Shulman M, Stephens KA, Watkins KE, **Weiss RD,** Wu LT. [The opioid use disorder core outcomes set \(OUD-COS\) for treatment research: findings from a Delphi consensus study.](#) Addiction. 2022 Sep;117(9):2438-2447. doi: 10.1111/add.15875. Epub 2022 Apr 25. PMID: 35293064; PMCID: PMC9543602.

Cowan E, Perrone J, **Dziura J, Edelman J, Hawk K,** Herring A, McCormack R, Alexandra M, Phadke M, **Fiellin DA, D'Onofrio G.** [Urine Toxicology Profiles of Emergency Department Patients with Untreated Opioid Use Disorder: A MultiSite View.](#) J Emerg Med. doi: 10.1016/j.jemermed.2023.06.007

Levy S, Minegishi M, Brogna M, Subramaniam G, McCormack J, **Weiss R, Weitzman ER.** [Comparing the Performance of WMH-CIDI-SAM in Adolescents to Diagnoses Made by Pediatric Addiction Medicine Specialists.](#) Journal of Addiction Medicine, in press.

Luo SX, Feaster DJ, Liu Y, Balise RR, Hu MC, Bouzoubaa L, Odom GJ, Brandt L, Pan Y, Hser YI, VanVeldhuisen P, Castillo F, Calderon AR, Rotrosen J, Saxon AJ, **Weiss RD,** Wall M, Nunes EV. [Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment.](#) JAMA Psychiatry. 2023 Oct 4:e233596. doi: 10.1001/jamapsychiatry.2023.3596. Epub ahead of print. PMID: 37792357; PMCID: PMC10551817.